Advertisement

Breast Cancer Research and Treatment

, Volume 109, Issue 2, pp 209–229 | Cite as

HER2/neu in systemic therapy for women with breast cancer: a systematic review

  • Bindi Dhesy-Thind
  • Kathleen I. Pritchard
  • Hans Messersmith
  • Frances O’Malley
  • Leela Elavathil
  • Maureen Trudeau
Review

Abstract

Background

Amplification and/or overexpression of the HER2/neu gene is associated with a poor prognosis in breast cancer. Many studies have suggested that this gene may be associated with the relative efficacy of chemotherapy and endocrine therapy options.

Methods

A systematic review of the evidence was conducted. MEDLINE, EMBASE, the Cochrane Library, the American Society of Clinical Oncology annual meeting proceedings, and the San Antonio Breast Cancer Symposia proceedings were all searched to November 2006 for reports of analysis by HER2/neu status of the relative efficacy of the treatment arms in randomized controlled trials.

Results

Thirty-five trials were identified. A meta-analysis of trials of tamoxifen versus observation found no significant interaction between treatment and HER2/neu status, although one trial not included in the meta-analysis did find interaction. A meta-analysis of adjuvant anthracycline-based chemotherapy trials found a significant interaction (difference in disease-free survival log-hazard ratios −0.31, 95% confidence interval −0.50 to −0.13; difference in overall survival log-hazard ratios −0.34, 95% confidence interval −0.53 to −0.14). Significant interaction was also found in a meta-analysis of disease-free survival in trials of adjuvant taxane therapy versus non-taxane therapy (difference in disease-free survival log-hazard ratios −0.36, 95% confidence interval −0.68 to −0.04). HER2/neu overexpression and/or amplification was associated with greater efficacy of the anthracycline or taxane regimen.

Conclusions

Current evidence supports the conclusion that the benefit of both anthracycline-based and taxane-based adjuvant chemotherapy is associated on HER2/neu status, with patients with HER2/neu-positive cancers benefiting more from these therapies than those with HER2/neu-negative cancers.

Keywords

Breast cancer HER2/neu Systematic review Systemic therapy 

References

  1. 1.
    Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712PubMedCrossRefGoogle Scholar
  2. 2.
    O’Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA (1991) The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63(3):444–446PubMedGoogle Scholar
  3. 3.
    Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815–2834PubMedCrossRefGoogle Scholar
  4. 4.
    Review Manager (RevMan) [Computer Program]. Version 4.2.7 for Windows XP. Oxford: The Cochrane Collaboration, 2004. Available from: http://www.cc-ims.net/RevManGoogle Scholar
  5. 5.
    Knoop AS, Bentzen SM, Nielsen MM, Rasmussen BB, Rose C (2001) Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 19(14):3376–3384PubMedGoogle Scholar
  6. 6.
    De Placido S, De Laurentiis M, Carlomagno C, Gallo C, Perrone F, Pepe S et al (2003) Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 9(3):1039–1046PubMedGoogle Scholar
  7. 7.
    Blanco AR, De Laurentils, Carlomagno MC et al (1998) 20 year update of the Naples gun trial of adjuvant breast cancer therapy: evidence of interaction between c-erb-b2 expression and tamoxifen efficacy. Proc Am Soc Clin Oncol 17:A373Google Scholar
  8. 8.
    Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A’Hearn R et al (2006) Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor, and HER2 status. Ann Oncol 17:818–826PubMedCrossRefGoogle Scholar
  9. 9.
    CRC Adjuvant Breast Trial Working Party (1988) Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 57:604–607Google Scholar
  10. 10.
    Nolvadex Adjuvant Trial Organisation (1985) Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Lancet 1(8433):836–840Google Scholar
  11. 11.
    Rydén L, Jirström K, Bendahl P, Fernö M, Nordenskjöld B, Stål O et al (2005) Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 23(21):4695–4704PubMedCrossRefGoogle Scholar
  12. 12.
    Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group (1996) J Natl Cancer Inst 88(21):1543–1549Google Scholar
  13. 13.
    Stal O, Borg A, Ferno M, Kallstrom AC, Malmstrom P, Nordenskjold B (2000) ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 11(12):1545–1550PubMedCrossRefGoogle Scholar
  14. 14.
    Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19(18):3808–3816PubMedGoogle Scholar
  15. 15.
    Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J et al (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12(11):1527–1532PubMedCrossRefGoogle Scholar
  16. 16.
    Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU et al (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23(22):5108–5116PubMedCrossRefGoogle Scholar
  17. 17.
    Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA et al (2003) Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 21(10):1967–1972PubMedCrossRefGoogle Scholar
  18. 18.
    Jakesz R, Hausmaninger H, Kubista E et al (2002) The prognostic value of HER-2/neu status in premenopausal patients with hormone-responsive breast cancer. Breast Cancer Res Treat 76(Suppl 1):A128Google Scholar
  19. 19.
    Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T et al (2002) Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer – Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20(24):4621–4627PubMedCrossRefGoogle Scholar
  20. 20.
    Love RR, Duc NB, Allred DC, Binh NC, Dinh NV, Kha NN et al (2002) Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 20(10):2559–2566PubMedCrossRefGoogle Scholar
  21. 21.
    Love RR, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL et al (2003) Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21(3):453–457PubMedCrossRefGoogle Scholar
  22. 22.
    Ravdin PM, Green S, Albain KS et al (1998) Initial report of the SWOG biological correlative study of c-erbb-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen alone. Proc Am Soc Clin Oncol 17:A374Google Scholar
  23. 23.
    Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A et al (2001) HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 12(8):1081–1089PubMedCrossRefGoogle Scholar
  24. 24.
    Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G et al (2002) HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8(5):1107–1116PubMedGoogle Scholar
  25. 25.
    Petruzelka L, Pribylova O, Vedralova J et al (2000) C-erbB2 overexpression and treatment outcome in a randomized trial comparing adjuvant CMF and AC in equitoxic reiment in breast cancer. Proc Am Soc Clin Oncol 19:A534Google Scholar
  26. 26.
    Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV (2005) Retrospective analysis of topoisomerase IIa amplification and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23(30):7483–7490PubMedCrossRefGoogle Scholar
  27. 27.
    Colozza M, Bisagni G, Mosconi AM, Gori S, Boni C, Sabbatini R et al (2002) Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study. Eur J Cancer 38:2279–2288PubMedCrossRefGoogle Scholar
  28. 28.
    Colozza M, Sidoni A, Mosconi AM, Cavaliere A, Bisagni G, Gori S et al (2005) HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluoruracil with epirubicin in patients with stage I/II breast cancer: long-term results. Clin Breast Cancer 6(3):253–259PubMedCrossRefGoogle Scholar
  29. 29.
    De Laurentiis M, Caputo F, Massarelli E et al (2001) HER2 expression and anthracycline effect: results from the Naples GUN3 randomized trial. Proc Am Soc Clin Oncol 20:A133Google Scholar
  30. 30.
    De Placido S, Perrone F, Carlomagno C, Morabito A, Pagliarulo C, Lauria R et al (1995) CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). Br J Cancer 71(6):1283–1287PubMedGoogle Scholar
  31. 31.
    Moliterni A, Menard S, Valagussa P, Biganzoli E, Boracchi P, Balsari A et al (2003) HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol 21(3):458–462PubMedCrossRefGoogle Scholar
  32. 32.
    Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, bu-Zahra H et al (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group [see comment]. J Clin Oncol 16(8):2651–2658PubMedGoogle Scholar
  33. 33.
    Pritchard KI, Shepherd LE, O’Malley FP, Andrulis IL, Tu D, Bramwell VH et al (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354(20):2103–2111PubMedCrossRefGoogle Scholar
  34. 34.
    Fisher B, Redmond C, Wickerham DL, Bowman D, Schipper H, Wolmark N et al (1989) Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 7(5):572–582PubMedGoogle Scholar
  35. 35.
    Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D et al (1998) erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90(18):1361–1370PubMedCrossRefGoogle Scholar
  36. 36.
    Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG et al (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8(9):1483–1496PubMedGoogle Scholar
  37. 37.
    Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL et al (2000) HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 92(24):1991–1998PubMedCrossRefGoogle Scholar
  38. 38.
    Vera R, Albanell, Lirola JL et al (1999) HER2 overexpression as a predictor of survival in a trial comparing adjuvant FAC and CMF in breast cancer. Proc Am Soc Clin Oncol 18:A265Google Scholar
  39. 39.
    Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC et al (1998) erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90(18):1346–60PubMedCrossRefGoogle Scholar
  40. 40.
    Arnould L, Fargeot P, Bonneterre J et al (2003) Epirubicin does-response effect in node-positive breast cancer patients is independent of HER2 overexpression: 10-year retrospective analysis of French Adjuvant Study Group 05 trial. Breast Cancer Res Treat 76(Suppl 1):A538Google Scholar
  41. 41.
    Bonneterre J, Roche H, Kerbrat P et al (2003) French Adjuvant Study Group 05 trial (FEC 50 vs FEC 100): 10-year update of benefit/risk ratio after adjuvant chemotherapy (CT) in node-positive (N+), early breast cancer (EBC) patients (pts). Proc Am Soc Clin Oncol 22:24, A93Google Scholar
  42. 42.
    Del Mastro L, Bruzzi P, Venturini M et al (2004) HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in early breast cancer (BC) patients. J Clin Oncol 22(14 Suppl):A571Google Scholar
  43. 43.
    Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer [see comment]. N Engl J Med 349(1):7–16PubMedCrossRefGoogle Scholar
  44. 44.
    Rodenhuis S, Bontenbal M, Beex LV et al (2005) Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: Update of the Dutch Randomized Trial. J Clin Oncol 23(16S):A672Google Scholar
  45. 45.
    Rodenhuis S, Bontenbal M, Tjan-Heijnen VC, van der Wall E, Smit WM, Nooij MA et al (2005) Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer [slides on the Internet] [abstract 672]. In: 2005 ASCO Annual Meeting. Available from: http://www.asco.org/ac/1,1003,_12-002511-00_18-0034-00_19-002775,00.asp. Cited 12 Oct 2005Google Scholar
  46. 46.
    Rodenhuis S, Bontenbal M, van Hoesel QGCM, Smit WM, Nooij MA, Voest EE et al (2006) Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 17:588–596PubMedCrossRefGoogle Scholar
  47. 47.
    Konecny GE, Thomssen C, Luck HJ, Untch M, Wang HJ, Kuhn W et al (2004) Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 96(15):1141–1151PubMedCrossRefGoogle Scholar
  48. 48.
    Luck H, Thomssen C, Untch M et al (2000) Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin cyclophosphamide (EC). A study of the AGO Breast Cancer Group. Proc Am Soc Clin Oncol 19:A280Google Scholar
  49. 49.
    Hamilton A, Larsimont D, Paridaens R, Drijkoningen M, van d V, Bruning P et al (2000) A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clin Breast Cancer 1(3):233–240Google Scholar
  50. 50.
    Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S et al (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18(4):724–733PubMedGoogle Scholar
  51. 51.
    Sjostrom J, Collan J, von Boguslawski K, Franssila K, Bengtsson NO, Mjaaland I et al (2002) C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. Eur J Cancer 38(4):535–542PubMedCrossRefGoogle Scholar
  52. 52.
    Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO et al (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35(8):1194–1201PubMedCrossRefGoogle Scholar
  53. 53.
    Di Leo A, Chan S, Paesmans M, Friedrichs K, Pinter T, Cocquyt V et al (2005) HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat 86:197–206CrossRefGoogle Scholar
  54. 54.
    Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla J-P, Weaver C et al (2005) Aduvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302–2313PubMedCrossRefGoogle Scholar
  55. 55.
    Hayes DF, Thor A, Dressler L et al (2006) HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. J Clin Oncol 24(18S):A510Google Scholar
  56. 56.
    Hayes DF (2006) HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer [slides on the internet] [abstract 510]. In: 2006 ASCO Annual Meeting. Available from: http://www.asco.org/portal/site/ASCO/. Cited 24 Nov 2006Google Scholar
  57. 57.
    Kostopoulos I, Arapantoni-Dadioti P, Gogas H, Papadopoulos S, Malamou-Mitsi V, Scopa CD et al (2006) Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Breast Cancer Res Treat 96:251–261PubMedCrossRefGoogle Scholar
  58. 58.
    Learn PA, Yeh IT, McNutt M, Chisholm GB, Pollock BH, Rousseau DL Jr et al (2005) HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast cancer. Cancer 103(11):2252–2260PubMedCrossRefGoogle Scholar
  59. 59.
    Lin NU, Broadwater LG, Dressler S et al (2004) The predictive value of HER2 and p53 on outcomes after paclitaxel chemotherapy for metastatic breast cancer: results from CALBG 9342. J Clin Oncol 22(14 Suppl):A9562Google Scholar
  60. 60.
    Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support vs. triweekly epirubicin-paclitaxel in locally-advanced breast cancer. A S.I.C.O.G. phase III study [slides on the internet] [abstract 572] (2006) In: 2006 ASCO Annual Meeting. Available from: http://www.asco.org/portal/site/ASCO/. Cited 24 Nov 2006Google Scholar
  61. 61.
    Frasci G, D’Aiuto G, Comella P et al (2006) Weekly cisplatin-epirucibin-paclitaxel (PET) with granulocytic-colony stimulating factor support versus tri-weekly epirubicin-paclitaxel in locally advanced breast cancer: final comprehensive and subgroup analysis of a SICOG phase III study. J Clin Oncol 24(18S):A572Google Scholar
  62. 62.
    Pribylova O, Petruzelka L, Shumansky K et al (2005) Randomized trial of adjuvant equitoxic dose-escalated anthracycline (A)-containing regimen of doxorubicin, cyclophosphamide (AC) versus cyclophosphamide, methotrexate, 5-FU (CMF) for stage I-II breast cancer (BrCa): Can equitoxicity compensate for agent selection? J Clin Oncol 23(16S):A818Google Scholar
  63. 63.
    Dressler L, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S et al (2005) Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 23(19):4287–4297PubMedCrossRefGoogle Scholar
  64. 64.
    Hoang MP, Sahin AA, Ordonez NG, Sneige N (2000) HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 113(6):852–859PubMedCrossRefGoogle Scholar
  65. 65.
    Hsu CY, Ho DM, Yang CF, Lai CR, Yu IT, Chiang H (2002) Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest. Am J Clin Pathol 118(5):693–698PubMedCrossRefGoogle Scholar
  66. 66.
    Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA et al (2002) Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831 [see comment]. J Natl Cancer Inst 94(11):855–857PubMedGoogle Scholar
  67. 67.
    Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K et al (2002) Real-world performance of HER2 testing–National Surgical Adjuvant Breast and Bowel Project experience.[see comment]. J Natl Cancer Inst 94(11):852–854PubMedGoogle Scholar
  68. 68.
    ATAC Trialists Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62CrossRefGoogle Scholar
  69. 69.
    Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T et al (2004) A randomized trail of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350(11):1081–1092PubMedCrossRefGoogle Scholar
  70. 70.
    Thurlimann BJ, Keshaviah A, Mouridsen H, Mauriac L, Forbes JF, Paridaens R et al (2005) BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. J Clin Oncol 23(16S):A511Google Scholar
  71. 71.
    Dowsett M (2003) Analysis of time to recurrence in the ATAC (arimadex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 82(Suppl 1):A4Google Scholar
  72. 72.
    Viale G, Regan M, Dell’Orto P, Del Curto B, Braye S, Orosz Z et al (2005) Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 94(Suppl 1):A44Google Scholar
  73. 73.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1671PubMedCrossRefGoogle Scholar
  74. 74.
    Romond EH, Perez EA, Bryant J, Suman V, Geyer CE, Davidson N et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684PubMedCrossRefGoogle Scholar
  75. 75.
    Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A et al (1999) Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17(10):3058–3063PubMedGoogle Scholar
  76. 76.
    Piccart MJ, Di Leo A, Beauduin M, Vindevoghel A, Michel J, Focan C et al (2001) Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 19(12):3103–3110PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Bindi Dhesy-Thind
    • 1
  • Kathleen I. Pritchard
    • 2
  • Hans Messersmith
    • 3
  • Frances O’Malley
    • 4
  • Leela Elavathil
    • 5
  • Maureen Trudeau
    • 2
  1. 1.Juravinski Cancer CentreHamiltonCanada
  2. 2.Toronto Sunnybrook Regional Cancer CentreTorontoCanada
  3. 3.Cancer Care Ontario, Program in Evidence-Based Care, Department of Clinical Epidemiology and BiostatisticsMcMaster UniversityHamiltonCanada
  4. 4.Mount Sinai HospitalTorontoCanada
  5. 5.Henderson General HospitalHamiltonCanada

Personalised recommendations